Henry Gao

Mr. Henry Gao is Frontage Laboratories’ President of Asia Pacific operations. Henry is an accomplished professional with over 25 years of experience in privately held and publicly listed global organizations leading functions including finance, audit, investment, project management, general management, IPO, and M&As.

From 2018 to 2022 Henry was a member of the board of directors of Frontage Holdings Corporation. Henry’s board level and executive leadership has been well recognized in the CRO and the biotech industries in the APAC region and beyond.

Prior to this appointment, since September 2021, Henry was the executive director and CFO of Shanghai Duoning Biotechnology Co., Ltd. From November 2016 to September 2021, he was the board secretary, deputy general manager and CFO at Hangzhou Tigermed Consulting Co., Ltd. Prior to that and until October 2016, he has held the CFO and board secretary role at Shanghai Xiaoi Robot Technology Corporation Limited. From May 2011 to December 2015, he was the chief financial officer and board secretary of McWong Environmental Technology Corporation Limited.

Before that, Henry has held various positions in Hong Kong Shanghai Alliance Holdings Limited, City North Infrastructure Pty Ltd., Rio Tinto Group, and Felix Resources Ltd. From May 2001 to June 2007, he worked at Foster Wheeler AG in a variety of leadership roles including the China finance manager, chief compliance officer and project control director for Asia. He began his career with PWC Business Consulting in Shanghai, China.

Henry received his bachelor’s degree from Shanghai University of Finance & Economics, China, majoring in international accounting. He is a Certified Public Accountant in China, an internationally accredited Certified Internal Auditor, an Associate of the Chartered Institute of Management Accountants (UK), a member of the Association of International Certified Professional Accountants (US & UK) and a Fellow of the Association of Chartered Certified Accountants (UK).